1171

Reckitt Benckiser Group agreed to pay 200 million to to resolve multistate litigation alleging that it improperly marketed its opioid addiction treatment drug Suboxone and thus caused false claims to be submitted to state Medicaid programs. This was part of a larger 1.4 billion civil and criminal settlement involving the U.S. Department of Justice, which issued its own announcement (see separate # entry).